Skip to main content

Table 3 Therapy toxicities (>Grade 3)

From: Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study

 

Grade 3

Grade 4

Neutropenia

5 (12.5%)

1 (2.5%)

Anemia

6 (15.0%)

0 (0%)

Hypertension

3 (7.5%)

0 (0%)

Anorexia

3 (7.5%)

0 (0%)

Fatigue

3 (7.5%)

0 (0%)

Thromboembolic event

2 (5.0%)

0 (0%)

Jaw osteonecrosis a

2 (5.0%)

0 (0%)

Nausea

1 (2.5%)

0 (0%)

Oral mucositis

1 (2.5%)

0 (0%)

Tumor pain

1 (2.5%)

0 (0%)

Hyponatremia

1 (2.5%)

0 (0%)

Gastrointestinal perforation

0 (0%)

1 (2.5%)

  1. aThese two patients received denosumab